Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$3.62 -3.5%	$5.23	$3.39 ▼ $16.00	$39.20M	0.87	54,023 shs	62,597 shs
DERM Journey Medical	$7.77 +11.0%	$6.66	$3.46 ▼ $8.24	$179.52M	0.86	84,451 shs	171,387 shs
FDMT 4D Molecular Therapeutics	$3.42 -2.0%	$3.24	$2.24 ▼ $28.93	$158.43M	2.87	833,970 shs	293,635 shs
NLTX Neoleukin Therapeutics	$17.28 -4.2%	$13.66	$2.03 ▼ $14.36	$162.40M	1.11	50,104 shs	110,750 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	-3.47%	-11.71%	-24.27%	-45.97%	-72.37%
DERM Journey Medical	+11.00%	+12.94%	+4.02%	+38.75%	+115.83%
FDMT 4D Molecular Therapeutics	-2.01%	-11.17%	+2.40%	-28.75%	-86.40%
NLTX Neoleukin Therapeutics	0.00%	-11.48%	+12.13%	+4.10%	-46.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	3.5052 of 5 stars	4.4	5.0	0.0	0.0	0.6	1.7	1.3
DERM Journey Medical	1.8801 of 5 stars	3.6	2.0	0.0	0.0	1.1	1.7	0.6
FDMT 4D Molecular Therapeutics	3.1723 of 5 stars	4.3	2.0	0.0	0.0	3.6	1.7	0.6
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.83	Moderate Buy	$33.00	811.60% Upside
DERM Journey Medical	3.20	Buy	$9.88	27.09% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	764.20% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AVTX, NLTX, DERM, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/15/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/8/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
3/27/2025	DERM Journey Medical	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$10.50
3/27/2025	DERM Journey Medical	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/25/2025	AVTX Avalo Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform ➝ Buy	$23.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$441K	88.88	N/A	N/A	$9.11 per share	0.40
DERM Journey Medical	$56.24M	3.19	$0.27 per share	28.37	$1.05 per share	7.40
FDMT 4D Molecular Therapeutics	$23K	6,888.33	N/A	N/A	$7.20 per share	0.48
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$31.54M	N/A	0.00	N/A	N/A	N/A	-442.16%	122.99%	8/11/2025 (Estimated)
DERM Journey Medical	-$3.85M	-$0.39	N/A	N/A	N/A	-31.74%	-132.10%	-26.90%	8/11/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$100.84M	-$3.18	N/A	N/A	N/A	N/A	-28.00%	-26.16%	8/14/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A

Latest AVTX, NLTX, DERM, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DERM Journey Medical	-$0.24	-$0.18	+$0.06	-$0.18	$12.05 million	$13.14 million
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
3/26/2025	Q4 2024	DERM Journey Medical	-$0.22	$0.08	+$0.30	$0.08	$14.21 million	$14.30 million
2/28/2025	Q4 2024	FDMT 4D Molecular Therapeutics	-$0.80	-$0.90	-$0.10	-$0.90	$2.28 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	1.42	1.42
DERM Journey Medical	1.81	1.38	1.03
FDMT 4D Molecular Therapeutics	N/A	17.33	17.33
NLTX Neoleukin Therapeutics	N/A	15.33	15.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
DERM Journey Medical	7.25%
FDMT 4D Molecular Therapeutics	99.27%
NLTX Neoleukin Therapeutics	52.37%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	3.03%
DERM Journey Medical	15.03%
FDMT 4D Molecular Therapeutics	9.60%
NLTX Neoleukin Therapeutics	1.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.37 million	Not Optionable
DERM Journey Medical	90	23.10 million	18.14 million	N/A
FDMT 4D Molecular Therapeutics	120	46.33 million	42.85 million	Optionable
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data

AVTX, NLTX, DERM, and FDMT Headlines

Recent News About These Companies

Neoleukin Therapeutics (NASDAQ:NLTX) Trading 27.3% Higher - What's Next?

May 19, 2025 | marketbeat.com

(NGNE) Proactive Strategies

October 18, 2024 | news.stocktradersdaily.com

Neurogene concludes merger deal with Neoleukin Therapeutics

December 20, 2023 | pharmaceutical-technology.com

Is Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?

December 20, 2023 | finance.yahoo.com

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

December 15, 2023 | finance.yahoo.com

Neoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and Dates

December 4, 2023 | benzinga.com

Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…

October 5, 2023 | markets.businessinsider.com

Neoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 26, 2023 | finanznachrichten.de

Neoleukin Thera (NASDAQ: NLTX) should be up 500% - it’s actually up 7%

September 26, 2023 | dhakatribune.com

Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

September 22, 2023 | finance.yahoo.com

Investing in Neoleukin Therapeutics Inc. [NLTX]: What You Must Know

August 21, 2023 | knoxdaily.com

Neoleukin Therapeutics Recent Insider Activity

August 18, 2023 | benzinga.com

BAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics Inc

August 18, 2023 | finance.yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCU

August 8, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX

August 1, 2023 | markets.businessinsider.com

Redmile Group, LLC Boosts Stake in Neoleukin Therapeutics Inc

July 28, 2023 | finance.yahoo.com

Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm

July 26, 2023 | benzinga.com

Analysts review Neoleukin Therapeutics Inc.’s rating

July 26, 2023 | knoxdaily.com

ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCF

July 24, 2023 | kentuckytoday.com

Baker Bros. Advisors Now Owns 19.99% of Neoleukin Therapeutics

July 24, 2023 | 247wallst.com

An Analysis of Neoleukin Therapeutics Inc. (NLTX)’s Potential Price Growth

July 19, 2023 | knoxdaily.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX, NLTX, DERM, and FDMT Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$3.62 -0.13 (-3.47%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$3.79 +0.17 (+4.70%)

As of 05/27/2025 07:49 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Journey Medical NASDAQ:DERM

$7.77 +0.77 (+11.00%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$7.80 +0.03 (+0.39%)

As of 05/27/2025 07:40 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

4D Molecular Therapeutics NASDAQ:FDMT

$3.42 -0.07 (-2.01%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$3.42 0.00 (0.00%)

As of 05/27/2025 04:22 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Neoleukin Therapeutics NASDAQ:NLTX

$17.28 -0.76 (-4.21%)

As of 05/23/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time